Brain Bleeds Strike About One in Fifty Newborns with Hemophilia, Meta-Analysis Finds

A newborn with hemophilia faces a roughly one-in-fifty chance of suffering a brain bleed in the first weeks of life, according to a new systematic review and meta-analysis published in BMC Pediatrics. The study, led by Manna Zheng and colleagues at Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine in China, pooled data from thirteen studies covering 5,845 live-born neonates with hemophilia and identified 131 cases of intracranial hemorrhage, or ICH, within the first twenty-eight days of life. The pooled cumulative incidence came out at 2.10 percent, with a 95 percent confidence interval of 1.40 to 2.79 percent. Although that figure may sound modest, the authors emphasize that neonatal ICH is among the most devastating complications a child with hemophilia can experience, capable of causing lifelong neurological disability or death within days of birth.

Hemophilia is an inherited bleeding disorder caused by deficiencies in clotting factor VIII, in the case of hemophilia A, or factor IX, in the case of hemophilia B. Because these proteins are essential for forming stable blood clots, affected individuals bleed for longer than normal after injury and can bleed spontaneously into joints, muscles, and, most dangerously, the brain. The disorder is passed on through the X chromosome, so it overwhelmingly affects boys, while girls are typically carriers. What makes the neonatal period so treacherous is the combination of an immature coagulation system, the mechanical stresses of labor and delivery, and the fact that many affected infants are born into families with no known history of the disease. In roughly a third of cases, hemophilia appears in a child with no prior family history, arising from a new genetic mutation, which means neither obstetricians nor parents may anticipate the bleeding risk before delivery.

Intracranial hemorrhage in a newborn is a medical emergency of the highest order. Bleeding can occur in several compartments of the skull: inside the brain tissue itself, in the subdural space beneath the dura mater, in the subarachnoid space surrounding the brain, or within the ventricles, the fluid-filled cavities deep in the brain. In a baby with hemophilia, even a minor trauma during delivery, such as the pressure of forceps, a vacuum extraction, or a prolonged second stage of labor, can trigger bleeding that a healthy infant’s clotting system would quickly contain. Symptoms may include seizures, lethargy, vomiting, a bulging fontanelle, pallor, or simply poor feeding and irritability, and because these signs overlap with many other neonatal conditions, diagnosis is often delayed. Untreated, the bleed can expand, compressing brain tissue and causing permanent damage or death.

The true scale of the problem has long been difficult to pin down. Previous estimates of neonatal ICH risk in hemophilia have ranged widely across the literature, from figures below one percent to reports suggesting rates several times higher. The authors of the new analysis attribute this fragmentation to heterogeneous study designs, small single-center cohorts, differing diagnostic criteria, and inconsistent surveillance practices. Some studies relied on clinical symptoms alone, others on routine cranial imaging, and the era in which each study was conducted matters as well, since the availability of neonatal ultrasound, computed tomography, and magnetic resonance imaging has changed dramatically over recent decades. By systematically searching PubMed, Embase, and Scopus from their inception through November 2025 and applying consistent eligibility criteria, requiring reported ICH within the first twenty-eight days of life among live-born neonates with hemophilia, the team sought to produce the most reliable estimate to date.

The statistical machinery behind the study is standard for modern evidence synthesis but worth unpacking. Rather than simply averaging the results of the thirteen included studies, the researchers used a random-effects meta-analysis, a model that assumes each study estimates its own true incidence and that these true values are distributed around a common mean. This approach is appropriate when between-study heterogeneity is high, which the authors confirmed it was. Heterogeneity in this context means the studies differed substantially in their reported rates, likely reflecting differences in geography, era, severity of hemophilia represented, mode of delivery, and intensity of diagnostic workup. The random-effects model widens the confidence interval to account for this variability, which is why the pooled estimate of 2.10 percent carries an interval stretching from 1.40 to 2.79 percent rather than a razor-thin range.

One of the more sobering findings concerns mortality. The pooled estimate for fatal neonatal ICH was approximately 0.2 percent, with a 95 percent confidence interval of 0.0 to 1.2 percent. In other words, among every thousand live-born neonates with hemophilia, roughly two may die from a brain bleed in the first month of life, though the wide interval reflects the rarity of the event and the limits of the available data. Fatal bleeds were rare in absolute terms, but the analysis underscores that when ICH does occur, it carries the potential for catastrophic outcomes. Survivors of neonatal ICH can face cerebral palsy, epilepsy, developmental delay, and cognitive impairment, making prevention far more valuable than even the best acute treatment.

Prevention, the authors argue, hinges on three pillars: early diagnosis, careful perinatal management, and avoidance of traumatic delivery techniques. Early diagnosis means identifying at-risk infants before or immediately after birth, ideally through known family history, carrier testing, or, in some health systems, targeted newborn screening of male infants born to carrier mothers. Careful perinatal management involves coordinating obstetric and hematology teams well before delivery, planning the mode of birth to minimize trauma, and avoiding invasive monitoring such as fetal scalp electrodes or vacuum and rotational forceps deliveries when a baby is known or suspected to have hemophilia. For infants diagnosed after birth, prompt replacement of the missing clotting factor can halt bleeding before it spreads, and some guidelines recommend prophylactic factor replacement for high-risk neonates during the vulnerable first days of life.

The study’s findings arrive amid a broader shift in hemophilia care. Prophylactic clotting factor infusions, once reserved for older children with severe disease, are increasingly considered earlier, and newer agents, including extended half-life factor products and bispecific antibodies that mimic factor VIII activity, have transformed long-term management. Yet the neonatal window remains a blind spot in many treatment pathways, because diagnosis itself may lag behind the highest-risk period. The authors call for dedicated neonatal-focused registries and prospective studies to refine risk stratification, arguing that only systematically collected, individual-level data can identify which babies are most likely to bleed and which preventive strategies work best. Such registries could track delivery mode, factor levels at birth, family history, imaging findings, and outcomes in a standardized way across centers and countries.

The meta-analysis also highlights persistent gaps in the evidence base. The thirteen included studies spanned different decades, healthcare settings, and diagnostic standards, and the authors note that the substantial heterogeneity between them limits the precision of any single pooled estimate. Retrospective designs dominated, and few studies distinguished between severity categories of hemophilia, modes of delivery, or the timing and type of diagnostic imaging. Without prospective, standardized surveillance, some bleeds may go undetected, particularly small hemorrhages that produce subtle or absent symptoms in the first days of life. This means the true incidence could, in principle, be higher than the pooled estimate suggests, a possibility the authors acknowledge indirectly through their call for better data.

For clinicians and families, the practical message is clear. A 2.10 percent risk is low enough that most newborns with hemophilia will never experience a brain bleed, but high enough that every birth should be treated as an opportunity for prevention. When hemophilia is known or suspected before delivery, obstetric teams can choose the least traumatic route of birth, neonatologists can maintain a low threshold for cranial imaging, and hematologists can have replacement factor ready at the bedside. When there is no family history, the challenge is harder, but the growing availability of genetic carrier screening and heightened awareness among providers can shorten the path from first symptom to diagnosis and treatment. The study, published open access on October 6, 2026, and citable under DOI 10.1186/s12887-026-07750-1, adds a carefully quantified data point to a field that has long operated on fragmented numbers, and it makes a compelling case that the first twenty-eight days of life deserve far more systematic attention in the care of children with hemophilia.

Subject of Research: Neonatal intracranial hemorrhage risk in infants with hemophilia

Article Title: Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis

Article References: Zheng, M., Zheng, H., Li, Y., & Tu, J. (2026). Risk of intracranial hemorrhage in neonates with hemophilia: a systematic review and meta-analysis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07750-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07750-1

Keywords: hemophilia, intracranial hemorrhage, neonatology, meta-analysis, systematic review, clotting factors, bleeding disorders, perinatal care, newborn screening, prophylaxis, BMC Pediatrics, birth trauma